Researchers at The University of Texas MD Anderson Cancer Center have developed a bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occurring tumor alterations. In retrospective validation studies, the tool selected combinations that resulted in improved patient outcomes across both pre-clinical and clinical studies.
The University of Texas MD Anderson Cancer Center on March 31 broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range of cancer services closer to those living in Southwest Houston and the surrounding areas.
